Cargando…
Statins: a repurposed drug to fight cancer
As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and ind...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306262/ https://www.ncbi.nlm.nih.gov/pubmed/34303383 http://dx.doi.org/10.1186/s13046-021-02041-2 |
_version_ | 1783727767205969920 |
---|---|
author | Jiang, Wen Hu, Jin-Wei He, Xu-Ran Jin, Wei-Lin He, Xin-Yang |
author_facet | Jiang, Wen Hu, Jin-Wei He, Xu-Ran Jin, Wei-Lin He, Xin-Yang |
author_sort | Jiang, Wen |
collection | PubMed |
description | As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins. |
format | Online Article Text |
id | pubmed-8306262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83062622021-07-28 Statins: a repurposed drug to fight cancer Jiang, Wen Hu, Jin-Wei He, Xu-Ran Jin, Wei-Lin He, Xin-Yang J Exp Clin Cancer Res Review As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins. BioMed Central 2021-07-24 /pmc/articles/PMC8306262/ /pubmed/34303383 http://dx.doi.org/10.1186/s13046-021-02041-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Jiang, Wen Hu, Jin-Wei He, Xu-Ran Jin, Wei-Lin He, Xin-Yang Statins: a repurposed drug to fight cancer |
title | Statins: a repurposed drug to fight cancer |
title_full | Statins: a repurposed drug to fight cancer |
title_fullStr | Statins: a repurposed drug to fight cancer |
title_full_unstemmed | Statins: a repurposed drug to fight cancer |
title_short | Statins: a repurposed drug to fight cancer |
title_sort | statins: a repurposed drug to fight cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306262/ https://www.ncbi.nlm.nih.gov/pubmed/34303383 http://dx.doi.org/10.1186/s13046-021-02041-2 |
work_keys_str_mv | AT jiangwen statinsarepurposeddrugtofightcancer AT hujinwei statinsarepurposeddrugtofightcancer AT hexuran statinsarepurposeddrugtofightcancer AT jinweilin statinsarepurposeddrugtofightcancer AT hexinyang statinsarepurposeddrugtofightcancer |